Vaksine mot vannkopper i Sør-Korea gikk ikke helt etter planen

Eller gjorde de det? Det er sannelig ikke godt å gi et sikkert svar på i dagens kaotiske verden der alt synes være motsatt av det vi har lært.

Sitatene som mine kommentarer er bygt på komme fra det tidligere direktør for Cicero UiO, Pål Prestrud, ville kalt et tungt, fagfellevurdert forskninsmagasin. Først kort om dette magasinet.

Clinical and Vaccine Immunology (CVI) is a peer-reviewed journal published by the American Society for Microbiology. CVI enhances our understanding of the immune response in health and disease by showcasing important clinically relevant research, including new animal models for human immunologic diseases, viral immunology, immunopathogenesis, and clinical laboratory immunology. In particular, the journal highlights important discoveries in immunization and vaccine research, such as the development and evaluation of vaccines, human and animal immune responses to vaccines, vaccine vectors, adjuvants and immunomodulators, quantitative assays of vaccine efficacy, and clinical trials. The journal publishes primary research articles,editorials, commentaries, minireviews, and case reports. Articles are freely accessible after 6 months (delayed open access). Through its «Global Outreach Program,» free online access is available to qualified microbiologists in eligible developing countries.

The journal serves ASM members and the broad research community with the high scientific and editorial standards of the ASM Journals and the society itself. It has been named a Rising Star among journals in the field of Immunology in Essential Science Indicators from Thomson Reuters for several months during 2010 and 2011. CVI’s impact factor has increased steadily for the last 5 years.

Vaksineprogrammet mot vannkopper i Sør-Korea førte til en tredobling barn som fikk vannkopper

Her er fra publikasjonen, halvfete uthevinger er gjort av meg:

ABSTRACT

With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54%. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67% and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.

Dette er sant og si ikke et særfenomen. I alle nasjoner og nesten med alle vaksiner, har det blitt observert lignende tilfeller. Vaksinene i seg selv gir ingen beskyttelse, og da sitter en igjen med bivirkningene av vaksinene, enten et utbrudd av sykdommen de var ment å kurere, eller enda mer alvorlige bivirkninger, så som lammelse og død. Her er mer:

INTRODUCTION

Varicella caused by varicella-zoster virus (VZV) is a highly infectious disease, and the secondary attack rates may reach up to 90% for susceptible household contacts. In South Korea, a live attenuated Biken Oka strain varicella vaccine was first introduced in 1988, and since then a few more imported and domestic vaccines have been on the market for different lengths of time. Among the few domestic vaccines which were developed in the early 1990s, only Suduvax (Green Cross, South Korea) is currently on the market and is the most popular varicella vaccine in South Korea. With the increase of varicella vaccine coverage in South Korea, varicella became a nationally notifiable disease, and the vaccine was mandated for universal immunization at government expense in 2005; routine varicella immunization for infants at 12 to 15 months of age was recommended. These measures should have reduced the burden of varicella in South Korea. However, the nationwide occurrence of varicella has not decreased substantially.

Minner meg litt om stoff jeg har lest om at ingen steder finnes så mange tilfeller av kikhoste som der det har blitt gjennomført et vaksineprogram mot nettopp kikhoste. Jeg anbefaler alle å ha den forfalskede svineinfluensapandemien i bakhodet. Den beskyttet ikke noen. Tvert imot gjorde den folk syke, og noen døde. Det finnes enda verre eksempler, men noe må jeg jo ha å skrive om senere.

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018876/
http://en.wikipedia.org/wiki/Clinical_and_Vaccine_Immunology

Legg igjen en kommentar

Din e-postadresse vil ikke bli publisert. Obligatoriske felt er merket med *

Optionally add an image (JPEG only)

%d bloggere liker dette: